Background Immune checkpoint inhibitors (ICIs) have become one of the standard treatment
options for advanced lung cancer. However, adverse events (AEs), particularly immune …

Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of
cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in …

Simple Summary This study systematically reviewed case reports to identify rare adverse
events in small cell lung cancer (SCLC) patients treated with immune checkpoint inhibitors …

Small cell lung cancer (SCLC) is the most malignant lung cancer with rapid growth and early
metastasis, but still lacks effective targeted therapies to improve the prognosis. Here, we …

Background Currently, there is a lack of well-established markers to predict the efficacy of
chemoimmunotherapy in small-cell lung cancer (SCLC). Neutrophil-to-lymphocyte ratio …

Patients receiving PD-(L) 1 inhibitors frequently encounter unusual side effects known as
immune-related adverse events (irAEs). However, the correlation of irAEs development with …

Background/Aim: Atezolizumab, an anti-PD-L1 antibody, has been increasingly
administered in combination with chemotherapy to patients with small cell lung cancer …

This study aimed to examine the effects of surgical resection on the treatment of limited-
stage small cell lung cancer and identify patient characteristics that may indicate a benefit …